PINK1 (N-terminal)

PINK1 (N-terminal)

• Background: This peptide is the immunogen used to make Cat # X2759P. _x000B__x000B_Protects against mitochondrial dysfunction during cellular stress, potentially by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy). It is necessary for PARK2 recruitment to dysfunctional mitochondria to initiate their degradation. Defects in PINK1 are the cause of Parkinson disease type 6 (PARK6). A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. Blocking Peptide to Cat # X2759P.
• Synonyms: PTEN-induced putative kinase Protein 1
• UniProt: Q9BXM7
• Type: Blocking Peptide
• Applications: Blocking Peptide
• Assay Principle: Optimal concentration should be evaluated by serial dilutions.
• Stability: See expiration date on vial
• Concentration: See vial for Concentration
• Form: Provided as solution in phosphate buffered saline with 0,08% sodium azide
• Precautions: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.
• Shipping Conditions: Ambient Temperature, freeze upon arrival
• Storage Conditions: Product should be stored at -20ºC; Aliquot to avoid freeze/thaw cycles
• Functional Analysis: Neutralizing